文献速递基础与转化研究临床试验与 GCP流行病学与生物统计

基于FADS Indel基因型的DHA剂量调整以减少早产与过期妊娠:ADORE随机试验二次分析

Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial.
PubMed 文献 · PLoS Med · 2026-10-08

该研究为ADORE随机试验的事后二次分析,纳入761名孕妇,按FADS Indel基因型(D/D、I/D、I/I)分层,比较200 mg/d与1,000 mg/d DHA对早产和过期妊娠的影响。结果显示,携带I等位基因者接受高剂量DHA后早产和早期早产率降低,而D/D基因型者高剂量DHA与过期妊娠增加相关,提示FADS Indel可作为DHA剂量反应的预测生物标志物。

要点

  • FADS Indel I等位基因携带者低剂量DHA时早期早产风险高于D/D型。
  • 高剂量DHA(1,000 mg/d)可降低I等位基因携带者的早期早产和早产风险。
  • D/D基因型者高剂量DHA与过期妊娠(≥40周)增加相关。

核心结论

  • FADS Indel基因型可预测孕期DHA剂量对早期早产和过期妊娠的效应方向。
  • I等位基因携带者高剂量DHA降低早期早产,D/D型高剂量DHA则过期妊娠更常见。

研究设计与样本

  • ADORE随机试验(NCT02626299)的事后二次分析,纳入761名孕妇。
  • 受试者随机接受200或1,000 mg/d DHA,并检测FADS Indel基因型(D/D、I/D、I/I)。

主要发现

  • I等位基因携带者低剂量DHA组早期早产率为4.3%(9/214;95% CrI [2.0%, 7.3%]),D/D组为0.8%(1/151;95% CrI [0.04%, 2.7%];PP=0.99)。
  • I等位基因携带者低剂量DHA组早产率为14.5%(31/214;95% CrI [10.1%, 19.5%]),D/D组为8.7%(13/151;95% CrI [4.7%, 13.6%];PP=0.96)。
  • I等位基因携带者高剂量DHA组早期早产率为1.1%(2/205;95% CrI [0.2%, 2.8%];PP=0.99),早产率为9.3%(19/205;95% CrI [5.7%, 13.6%];PP=0.95)。
  • 基因型与剂量对早期早产和过期妊娠的交互作用后验概率分别为PP=0.99和PP=0.98。
  • 高剂量DHA下两种基因型的早产率降低相似(PP=0.56)。

关键数值与推荐

  • FADS Indel为唯一检测的遗传变异,基于机制选择,基因分型对结局设盲。
  • 主要结局为早期早产(<34周)和早产(<37周),采用治疗特异性贝叶斯二项模型分析。
  • 宫颈长度在574名参与者中评估。

临床怎么用

  • 对携带FADS Indel I等位基因的孕妇,可考虑高剂量DHA(1,000 mg/d)以降低早期早产风险。
  • 对D/D基因型孕妇,高剂量DHA可能增加过期妊娠风险,需权衡剂量。
  • 基因型指导的DHA剂量策略有望优化不同种族/民族人群的妊娠时长。

局限性

  • 本研究为事后二次分析,基因型-剂量比较非试验预设目标。
  • 部分亚组早产和早期早产事件数少,尤其早产估计需谨慎解读。
  • 结果需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spontaneous early preterm birth (EPB < 34 weeks) is a major contributor to newborn morbidity and mortality; it depends on ancestry, and preventive measures are limited. The insertion (I) allele of the fatty acid desaturase (FADS) Indel polymorphism (rs66698963) modulates FADS1 expression, and increases arachidonic acid synthesis, enhancing parturifacient prostaglandins. Omega-3 docosahexaenoic acid (DHA) inhibits this pathway. Whether FADS Indel genotype predicts response to DHA dose in pregnancy is unknown. METHODS AND FINDINGS: To determine whether FADS Indel genotype modifies the effect of DHA dose on gestational length, we conducted a post hoc secondary analysis of the Assessment of DHA on Reducing Early Preterm Birth (ADORE) trial (NCT02626299). The FADS Indel, the only genetic variant measured, was selected on mechanistic grounds and genotyped blind to outcome. The analysis included all participants consenting to genetic analysis (12-20 weeks gestation) at three US medical centers. Participants received 200 or 1,000 mg/d DHA and were genotyped for FADS Indel (D/D, I/D, I/I). Primary outcomes were EPB and preterm birth (PB, <37 weeks) analyzed using treatment-specific Bayesian binomial models. Cervical length was assessed in 574 participants. Women (n = 10,497) were screened for eligibility from June 8th 2016, to March 13th 2020, 1,032 (1,000 mg, n = 540; 200 mg, n = 492) completed the ADORE trial. A total of 761 (1,000 mg, n = 396; 200 mg, n = 365) are included in this secondary analysis. Participants carrying at least one FADS Indel I allele (I/I + I/D) receiving low-dose DHA had 4.3% EPB (9/214; 95% Credible Interval (CrI) [2.0%, 7.3%]) versus 0.8% in the D/D group (1/151; 95% CrI [0.04%, 2.7%]; Posterior Probability (PP) = 0.99), and 14.5% PB (31/214; 95% CrI [10.1%, 19.5%]) versus 8.7% in the D/D group (13/151; 95% CrI [4.7%, 13.6%]; PP = 0.96). High-dose DHA was associated with reduced EPB in the I-allele group (1.1%; 2/205; 95% CrI [0.2%, 2.8%]; PP = 0.99), and PB (9.3%; 19/205; 95% CrI [5.7%, 13.6%]; PP = 0.95), with little effect in the D/D group. Birth at ≥40 weeks was more frequent in the high-dose D/D group. Black women had higher rates of PB and EPB, have higher rates of the I allele, and benefited most from 1,000 mg/d dose. These dose effects credibly differ by genotype for EPB and prolonged gestation (genotype × dose interaction PP = 0.99 and 0.98). Both genotypes reduced PB similarly with high-dose DHA (PP = 0.56). Although genetic analysis was anticipated and genotyping was completed blind to outcome, this was a post hoc analysis and the genotype-by-dose comparison was not a prespecified trial aim. Some subgroups contained few PB and EPB events, so these estimates, particularly for PB, should be interpreted cautiously and confirmed prospectively. CONCLUSIONS: The FADS Indel is a functional, mechanistically grounded polymorphism whose frequency varies with race/ethnicity. Preterm and early preterm birth were lower in the I-allele group receiving high-dose DHA (1,000 mg/d), while prolonged gestation was more frequent in the D/D group receiving high-dose DHA. FADS Indel genotypes predicted the direction of the response to high-dose DHA for EPB and prolonged gestation, whereas its modest PB benefit was shared by both genotypes. Analysis by retrospectively pairing high dose to I-carrier genotype and low dose to D/D was associated with the highest proportion of births at 37-40 weeks. These findings identify the FADS Indel as a potential predictive biomarker for DHA dose response and support a genotype-informed, precision-medicine strategy to optimize gestational length by reducing preterm birth in the I-allele group and prolonged gestation in the D/D group across racially/ethnically diverse populations. TRIAL REGISTRATION: Clinical trial identification number: NCT02626299, Date of registration: December 8, 2015, Date of Initial participant enrolled: June 8, 2016 https://clinicaltrials.gov/study/NCT02626299.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Li YN, Kothapalli KSD, Carlson SE, et al. Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial. PLoS Med. 2026. PMID: 42848825. doi:10.1371/journal.pmed.1005274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。